2024
A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology
D'Amico S, Sauta E, Asti G, Delleani M, Zazzetti E, Campagna A, Lanino L, Maggioni G, Ubezio M, Todisco G, Russo A, Tentori C, Buizza A, Franchi M, Dall'Olio L, Bicchieri M, Zampini M, Brindisi M, Ficara F, Riva E, Ventura D, Crisafulli L, Pinocchio N, Della Porta A, Jacobs F, Zambelli A, Savevski V, Santoro A, Sole F, Platzbecker U, Fenaux P, Diez-Campelo M, Garcia-Manero G, Haferlach T, Kordasti S, Castellani G, Efficace F, Santini V, Zeidan A, Komrokji R, Della Porta M. A Comprehensive, Artificial Intelligence, Digital Twin Platform Based on Multimodal Real-World Data Integration for Personalized Medicine in Hematology. Blood 2024, 144: 2221-2221. DOI: 10.1182/blood-2024-209634.Peer-Reviewed Original ResearchArtificial intelligenceData sharingDigital twinFederated learning platformSynthetic data generatorSHapley Additive exPlanationsImage dataDT platformDecision support systemMultimodal longitudinal dataAI-based toolsUnstructured informationAI frameworkData model formatElectronic health recordsMultimodal dataMultimodal informationPatient informationData integrationAI modelsData generationCentral repositoryTechnology implementation methodMultiple sources of informationReal world
2023
Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States
Zeidan A, Pollyea D, Borate U, Vasconcelos A, Potluri R, Rotter D, Kiendrebeogo Z, Gaugler L, Prebet T, Strocchia M, Bonifacio G, Chen C. Venetoclax plus azacitidine compared with intensive chemotherapy as induction for patients with acute myeloid leukemia: retrospective analysis of an electronic medical record database in the United States. Annals Of Hematology 2023, 102: 749-754. PMID: 36732419, PMCID: PMC10285011, DOI: 10.1007/s00277-023-05109-5.Peer-Reviewed Original ResearchConceptsHematopoietic stem cell transplantAcute myeloid leukemiaRelapse-free survivalIntensive chemotherapyComplete remissionOverall survivalMyeloid leukemiaRetrospective analysisMedian relapse-free survivalElectronic medical record databaseFlatiron Health databaseMedian overall survivalStem cell transplantMedical record databaseElectronic health recordsHSCT ratesRelapse rateCell transplantControlled TrialsTreatment outcomesHealth databasesPatientsRecord databaseMonthsHealth records
2019
Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents.
Giri S, Huntington S, Wang R, Zeidan A, Podoltsev N, Gore S, Ma X, Gross C, Davidoff A, Neparidze N. Chromosome 1 abnormalities and clinical outcomes in multiple myeloma in the era of novel agents. Journal Of Clinical Oncology 2019, 37: 8044-8044. DOI: 10.1200/jco.2019.37.15_suppl.8044.Peer-Reviewed Original ResearchOverall survivalMultiple myelomaPerformance statusMultivariable Cox survival analysisMedian overall survivalPoor performance statusLines of therapyKaplan-Meier methodCox regression analysisDays of diagnosisWorse overall survivalCox survival analysisLog-rank testReal-world treatmentCommon genetic mutationsHigh-risk mutationsSitu hybridization testingElectronic health recordsISS stageReal-world practiceMedian ageMeier methodOS independentPrimary outcomeSpecific regimens